New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
07:12 EDTEVGN, BAYRYEvogene announces amendment to Bayer wheat agreement
Evogene (EVGN) announced an amendment to the remaining work plan under its collaboration with Bayer CropScience LP (BAYRY) for improved wheat. Pursuant to the amended work plan, Evogene will shift from discovery of additional genes and SNP’s to discovery of novel genomic promoters. Under the amended agreement, Evogene will continue in close teamwork with Bayer to utilize its ATHLETE discovery platform but will shift the focus from the discovery of additional genes and SNP's to identifying novel genomic promoters.
News For EVGN;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
13:37 EDTBAYRYPE firms may bid on Bayer's MaterialScience unit, Reuters says
Subscribe for More Information
October 20, 2014
07:11 EDTBAYRYAmerican Society for Reproductive Medicine to hold annual meeting
2014 Annual Meeting of ASRM is being held in Honolulu on October 18-22.
05:34 EDTEVGNEvogene, Embrapa too cooperate on castor cultivation in Brazil
The Brazilian Agricultural Research Corporation, or Embrapa, and Evogene announced the signing of a joint research agreement between Embrapa and Evofuel Ltd., Evogene's wholly-owned subsidiary, for the advancement of castor cultivation in Brazil. The cooperation will primarily focus on technologies for controlling castor-specific diseases as well as practices for castor cultivation in rotation with soybean. The agreement is set to bring Embrapa's substantial experience in research and development of castor together with Evofuel's proprietary castor varieties, which are adapted to mechanized harvest and modern agricultural protocols, to offer Brazilian growers a full-scale solution for an economically viable, sustainable, and large-scale cultivation of castor.
October 14, 2014
14:03 EDTBAYRYCompugen achieves second preclinical milestone under Bayer cancer collaboration
Compugen (CGEN) disclosed that it has achieved a second milestone in its cancer immunotherapy collaboration it entered last year with Bayer HealthCare (BAYRY). The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators. The milestone being announced relates to the second preclinical milestone for one of the checkpoint protein candidates.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use